The thesis
channel-pullback is a trend-aligned dip-buyer. It waits for a confirmed uptrend, then buys weakness into the lower regression channel or a volume-support shelf, aiming to exit near the upper channel or overhead resistance. It runs a 24-name large-cap universe spanning tech (AAPL, MSFT, NVDA), financials (JPM, V, MA), staples (PG, KO, COST) and energy (XOM, CVX). The logic is conventional and defensible: in a rising market, pullbacks to structural support offer favourable risk-reward entries.
Recent activity
The book is small — roughly $11,000 in paper capital — and currently sits entirely in cash, reporting $11,041.15 total after the 21 October run. The past week's scheduled runs were quiet: single executions on 14, 16 and 21 October, with nothing on the days in between and zero rejections, so execution is clean. The headline round-trip is NVDA: bought 9 shares at $220.45 on 14 October and sold at $220.92 on 21 October — a flat exit after a week. Earlier trades fared better in one case and worse in others: XOM was bought at $163.77 on 5 October and sold at $168.81 on 8 October (~3%), while PFE and KO were cycled with little to show for it.
Backtest and validation
Over 451 days the strategy returned 7.62% (4.19% CAGR), with a Sharpe of 0.40 and a 14.83% max drawdown. Win rate is only 39.4% across 137 trades — this is a let-winners-run profile where a minority of trades carries the result, not a high-hit-rate system. Turnover is a hefty 2,311%, though fees stayed trivial ($137 total) and FX cost nothing.
Walk-forward validation did not pass. Three of four folds were positive, and fold 3 (Jul–Dec 2025) was excellent: +20.68% at a 3.86 Sharpe with a tiny 3.26% drawdown. But fold 2 (Jan–Jul 2025) lost 11.42% at a −1.70 Sharpe — a reminder that the approach bleeds when trends stall. The deciding weakness is in the overfitting statistics: the Probabilistic Sharpe Ratio is a respectable 0.70, but the Deflated Sharpe Ratio — which discounts for the 7 trials run — collapses to 0.196. Out-of-sample return was 3.63% at a 0.74 Sharpe, roughly half the full-sample figure.
Strengths and risks
Strengths: a sound, interpretable thesis; a liquid, diversified universe; clean execution; and genuine edge in the right regime, as fold 3 shows. Risks: the strategy is regime-dependent and vulnerable to choppy or topping markets (fold 2), the sub-40% win rate demands discipline through losing streaks, and — most importantly — it has not cleared the validation gate. A DSR of 0.196 means we cannot yet distinguish this edge from luck across the trials performed.
Verdict: channel-pullback is a credible candidate, not a proven one. It stays live and paper-traded, but the honest read is "promising, unconfirmed." The question worth watching is whether the small recent trades compound into a track record the validation stats can eventually endorse.